Journal of the American Academy of Child & Adolescent Psychiatry
New researchTreatment of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA)
Key Words
Cited by (0)
Clinical guidance is available at the end of this article.
Supplemental material cited in this article is available online.
Dr. Fernández de la Cruz was fully supported and Dr. Simonoff was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and the Institute of Psychiatry, King’s College London. The Multimodal Treatment Study of Children With ADHD (MTA) has been supported by the following grant numbers: U01MH50440, U01MH50447, U01MH50453, U01MH50454, U01MH50461, U01MH50467, and the following contract numbers: N01MH12004, N01MH12007, N01MH12008, N01MH12009, N01MH12010, N01MH12011, N01MH12012; HHSN271200800003-C, HHSN271200800004-C, HHSN271200800005-C, HHSN271200800006-C, HHSN271200800007-C, HHSN271200800008-C, and HHSN271200800009-C. This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the Department of Health, the MTA Study Investigators, the National Institutes of Health (NIH), the NHS, or the NIHR.
John Hodsoll, PhD, of King’s College London served as the statistical expert for this research.
Disclosure: Dr. McGough has received grant or research support from NIH, NeuroSigma, Inc., Purdue Pharma L.P., and Shire Pharmaceuticals. He has served as a consultant to Akili Interactive Labs, Merck, Neurovance, and Sunovion. He has presented expert testimony for Shire. Dr. Arnold has received research funding from Curemark, Forest, Eli Lilly and Co., Neuropharm, Novartis, Noven, Shire, Young Living, NIH, and Autism Speaks, and has consulted with or been on advisory boards for Gowlings, Neuropharm, Novartis, Noven, Organon, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire, and Tris Pharma, and has received travel support from Noven. Dr. Stringaris has received grant or research support from the Wellcome Trust, the NIHR, and the Department of Health UK. He has received royalties from Cambridge University Press for his book The Maudsley Reader in Phenomenological Psychiatry. Drs. Fernández de la Cruz, Simonoff, and Halperin report no biomedical financial interests or potential conflicts of interest.